| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 49.28 | 1-year : | 51.38 |
| Resists | First : | 42.19 | Second : | 43.99 |
| Pivot price | 41.01  |
|||
| Supports | First : | 39.29 | Second : | 32.68 |
| MAs | MA(5) : | 40.27 |
MA(20) : | 41.52 |
| MA(100) : | 40.15 |
MA(250) : | 40.41 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 32.9 |
D(3) : | 22.5 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 50.2 | Low : | 31.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BAX ] has closed above bottom band by 46.1%. Bollinger Bands are 52.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 41.22 - 41.39 | 41.39 - 41.55 |
| Low: | 39.84 - 40.02 | 40.02 - 40.2 |
| Close: | 40.72 - 41.01 | 41.01 - 41.29 |
Sat, 20 Apr 2024
Zoetis To Buy Abaxis In $2 Billion Deal - AOL
Mon, 15 Apr 2024
St. Jude Medical Settles FDA Warnings Letter for Texas Plant - Yahoo Canada Shine On
Fri, 25 May 2018
Abaxis May Not Receive A New Offer (NASDAQ:ABAX-DEFUNCT-9997) - Seeking Alpha
Wed, 16 May 2018
Zoetis to Buy Abaxis for $2 Billion - Investopedia
Wed, 16 May 2018
Zoetis to Acquire Abaxis, a Leading Global Provider of Veterinary Point-of-Care Diagnostic Instruments - Business Wire
Wed, 04 Apr 2018
Top Reasons Why I Like Abaxis In 2018 (NASDAQ:ABAX-DEFUNCT-9997) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 509 (M) |
| Shares Float | 505 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 92.4 (%) |
| Shares Short | 7,620 (K) |
| Shares Short P.Month | 8,130 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.54 |
| Profit Margin | 17.9 % |
| Operating Margin | 12 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 29.07 |
| EBITDA (p.s.) | 5.45 |
| Qtrly Earnings Growth | 33.7 % |
| Operating Cash Flow | 1,730 (M) |
| Levered Free Cash Flow | 1,700 (M) |
| PE Ratio | -272.17 |
| PEG Ratio | 3.3 |
| Price to Book value | 2.46 |
| Price to Sales | 1.4 |
| Price to Cash Flow | 12.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|